Novartis (NVS)
(Delayed Data from NYSE)
$105.33 USD
-0.80 (-0.75%)
Updated Jun 7, 2024 04:00 PM ET
Pre-Market: $105.11 -0.22 (-0.21%) 8:08 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
Novartis AG [NVS]
Reports for Purchase
Showing records 81 - 100 ( 477 total )
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 21123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended January 13.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 11123
Provider: Stock Traders Daily
Analyst: Research Department